Frontiers in Microbiology (Jun 2025)
Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques
- Jessica Coppola,
- Mara Parren,
- Raiza Bastidas,
- Karen Saye,
- Jacqueline Malvin,
- Joseph G. Jardine,
- Roxanne M. Gilbride,
- Sohita Ojha,
- Shana Feltham,
- David Morrow,
- Aaron Barber-Axthelm,
- Rachele Bochart,
- Randy Fast,
- Kelli Oswald,
- Rebecca Shoemaker,
- Jeffrey D. Lifson,
- Louis J. Picker,
- Dennis R. Burton,
- Scott G. Hansen
Affiliations
- Jessica Coppola
- Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States
- Mara Parren
- Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States
- Raiza Bastidas
- Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States
- Karen Saye
- Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States
- Jacqueline Malvin
- Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States
- Joseph G. Jardine
- Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States
- Roxanne M. Gilbride
- Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States
- Sohita Ojha
- Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States
- Shana Feltham
- Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States
- David Morrow
- Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States
- Aaron Barber-Axthelm
- Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States
- Rachele Bochart
- Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States
- Randy Fast
- AIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States
- Kelli Oswald
- AIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States
- Rebecca Shoemaker
- AIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States
- Jeffrey D. Lifson
- AIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States
- Louis J. Picker
- Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States
- Dennis R. Burton
- Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States
- Scott G. Hansen
- Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States
- DOI
- https://doi.org/10.3389/fmicb.2025.1592647
- Journal volume & issue
-
Vol. 16
Abstract
A vaccine is considered essential for controlling the HIV pandemic and ultimately eradicating AIDS. Neutralizing antibodies and MHC-E-restricted CD8+ T cells have shown the ability to protect against the simian counterpart of HIV, SIV, in rhesus macaques. In this study, we provide preliminary evidence that combining these orthogonal antiviral mechanisms can offer increased protection against SIV. Specifically, the replication arrest observed following vaccination with a rhesus cytomegalovirus (RhCMV/SIV)-based vaccine was enhanced by the presence of a passively administered neutralizing antibody at incompletely protective levels. This report encourages studies involving larger cohorts of macaques and alternative methods for administering neutralizing antibodies.
Keywords
